Genmab A/S (NASDAQ:GMAB) Given Consensus Rating of "Moderate Buy" by Brokerages

Genmab A/S (NASDAQ:GMAB - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $42.17.

A number of research analysts recently commented on GMAB shares. BMO Capital Markets reaffirmed an "outperform" rating and issued a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Sanford C. Bernstein upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Finally, Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research report on Thursday, February 13th.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Deep Track Capital LP purchased a new position in Genmab A/S during the 4th quarter worth $41,740,000. Renaissance Technologies LLC increased its stake in shares of Genmab A/S by 7.8% during the fourth quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company's stock worth $40,199,000 after acquiring an additional 139,722 shares during the period. Two Sigma Investments LP raised its holdings in Genmab A/S by 122.2% during the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock worth $35,612,000 after purchasing an additional 938,455 shares in the last quarter. Two Sigma Advisers LP lifted its position in Genmab A/S by 168.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock valued at $34,509,000 after purchasing an additional 1,038,400 shares during the period. Finally, First Trust Advisors LP boosted its holdings in Genmab A/S by 18.0% in the 4th quarter. First Trust Advisors LP now owns 1,644,288 shares of the company's stock valued at $34,316,000 after purchasing an additional 251,241 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Genmab A/S Price Performance

Shares of GMAB traded up $0.43 during mid-day trading on Wednesday, reaching $24.14. The company's stock had a trading volume of 803,338 shares, compared to its average volume of 861,444. Genmab A/S has a 12-month low of $18.64 and a 12-month high of $31.88. The stock has a market cap of $15.98 billion, a PE ratio of 13.87, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. The company's 50 day moving average is $21.28 and its 200 day moving average is $22.69.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, sell-side analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.